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Abstract: The red seaweed Laurencia viridis is a rich source of secondary metabolites 
derived from squalene. New  polyethers, such as  iubol  (2),  22-hydroxy-15(28)-
dehydrovenustatriol (3), 1,2-dehydropseudodehydrothyrsiferol (4), and secodehydrothyrsiferol 
(5) have been isolated and characterized from this alga. The structures were determined 
through the interpretation of NMR spectroscopic data and the relative configuration was 
proposed on the basis of NOESY spectrum and biogenetic considerations. All new 
compounds exhibited significant cytotoxic activity against a panel of cancer cell lines. 
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1. Introduction 
Within marine natural products, polyether metabolites encompass a unique class displaying a great 
diversity of structures and a broad array of bioactivities, acting as enzymatic inhibitors, ion channel 
blockers, stimulating neurotransmitters release or showing potent cytotoxic activities [1–4]. One 
important group of  squalene-derived polyethers, has been isolated  from red algae of the genus 
Laurencia and Chondria, (Rhodomelaceae family), sponges of the Axinellidae family, and from some 
mollusks [3–5]. Undoubtedly, the main source of these metabolites is the red alga Laurencia viridis, 
endemic algae of the Canary Islands that grow on basaltic rocks in the lower intertidal zone at early 
spring when the coastal temperature is about 18 °C [5,6]. Dehydrothyrsiferol (1), the major metabolite 
of this class, has shown important pharmacologic properties such as potent cytotoxic effects, protein 
phosphatase type 2A inhibition and integrin antagonist activity [7–11]. 
Further investigation of the minor constituents present in the fresh alga L. viridis  led to the   
isolation of four novel polyethers, iubol  (2),  22-hydroxy-15(28)-dehydrovenustatriol  (3),  
1,2-dehydropseudodehydrothyrsiferol (4) and secodehydrothyrsiferol  (5). Herein, we describe the 
isolation and structure determination of these compounds as well as their cytotoxic effects in several 
cancer cell lines (Figure 1).  
Figure 1. Structures of squalene-derived polyethers isolated from Laurencia viridis. 
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2. Results and Discussion 
Iubol (2), was isolated as an amorphous white solid, [α]
25
D +14.8 (c 0.27, CHCl3). The molecular 
formula, C30H51O6Br, determined by ESI-HRMS (m/z 609.3679/611.3607, [M + Na]
+), turned out to 
be identical to that found for dehydrothyrsiferol (1) [7,12]. The structure of 2 was mainly determined Mar. Drugs 2011, 9                     
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from the analysis of its NMR data. Interpretation of its 
1H and 
13C NMR spectra together with the 
examination of the HSQC experiment showed that 2 consists of seven methyls, eleven methylenes, six 
methines and six quaternary carbons. Analysis of the 
1H–
1H COSY spectra enabled us to set five 
independent proton-proton spin systems, in a similar way to that found in other polyethers isolated 
from L. viridis [5,7,8]. Specifically, the fragment C-1→C-18 of 2 closely resembles that of 1, with the 
presence of the same four spin systems: Fragment I  [H-3  (δH  3.89), H2-4  (δH  2.10/2.24), H2-5  
(δH 1.53/1.80)]; Fragment II [H-7 (δH 3.08), H2-8 (δH 1.45/1.72), H2-9 (δH 1.50/1.77)]; Fragment III  
[H-11 (δH 3.42), H2-12 (δH 1.63/1.78), H2-13 (δH 1.82/2.03), H-14 (δH 4.27)] and Fragment IV [H2-16 
(δH 2.12/2.46), H2-17  (δH 1.38), H-18  (δH 3.30)]  (Figure 2; Table 1).  On the other hand, notable 
differences were found towards the terminal moiety of the molecule (C-19→C-24), where the COSY 
spectrum revealed coupling between the characteristic proton H-22 (δH 3.38) and H2-21 (δH 1.75) and 
these sequentially to both H2-20 (δH 1.50/1.79). Finally, the structure of 2 was unambiguously assigned 
by the HMBC correlations. Thus, significant correlations between methyl H3-29 (δH 1.18) with C-18 
(δC 77.0), C-19 (δC 76.1) and C-20 (δC 27.9), as well as those of methyls H3-24 (δH 1.24) and H3-30  
(δH 1.25) with C-22 (δC 75.2) and C-23 (δC 75.7), were observed (Figure 2). 
Figure 2. Selected sections of the COSY and HMBC spectra of compound 2. 
1H–
1H spin 
systems are shown in blue lines, while arrows represent significant HMBC correlations. 
 
   
The high coincidence between the 
1H and 
13C NMR data of the C-1→C-14 fragment in 2 with those 
observed for 1 indicated that both compounds share the same relative configuration at C-3, C-6, C-7, 
C-10, C-11 and C-14 (Table 1). This conclusion was further supported by the analysis of the NOESY 
experiment,  where  identical  correlations  between  1  and  2  were observed. In particular, those Mar. Drugs 2011, 9                     
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connecting H-3 with H3-1 (δH 1.26), H-4α (δH 2.10) and H-5α (δH 1.53); H3-25 (δH 1.39) with H3-26 
(δH 1.20) as well as H-11 with H-7 and H-14 together with those of  H3-27 (δH 1.22) with H-8β  
(δH 1.45) and H-12β (δH 1.63) secured the relative configuration of this fragment. With regard to the  
C-18→C-24 fragment, when H-22 (δH 3.38, dd, J = 5.1, 10.5 Hz) was selectively irradiated in the  
1D-gNOESYexperiment, only H3-29 and H3-24 showed enhancements indicating that all protons are 
on the same side  of the tetrahydropyran  ring.  From  these coupling constant values and NOESY 
correlations we concluded that only a twist-boat conformation with 19R*, 22R* relative configuration 
is possible for the D ring, as shown in Figure 3. 
Figure 3. Significant dipolar correlations observed in NOESY experiments in 2. 
 
 
From a biogenetic viewpoint, most of the polyoxygenated squalene-derived ethers isolated from 
Laurencia species seem to arise from a common precursor: the (10R,11R)-squalene 10,11-epoxide 
isolated from L. okamurai. This compound can evolve to (6S,7S,10R,11R,14R,15R,18S,19S)-squalene 
tetraepoxide as a common intermediate [5]. Therefore, the new tetrahydropyran ring found in 2 could 
be biosynthesised from the diepoxide fragment 18S, 19S, 22R by protonation of the (20R)-epoxide 
followed by hydroxylation at C-23 yielding 18S, 19S-epoxy-20R-hydroxy as intermediate. The 
subsequent cyclization process with configuration inversion at C-19 would give the 18S*, 19R*, 22R* 
relative configuration as illustrated in Figure 4. Importantly, this hypothesis is consistent with the 
experimental data used to proffer the relative configuration of C-19 and C-22 offering simultaneously 
a solution for the configuration of C-18. 
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Table 1. NMR data (600 MHz, CDCl3, 298 K) for dehydrothyrsiferol (1) and iubol (2). 
  Dehydrothyrsiferol (1)  Iubol (2) 
Position  δC, mult.  δH (J in Hz)  HMBC 
a  δC, mult.  δH (J in Hz)  HMBC 
a 
1  31.0,  CH3  1.27, s  2, 3, 25  31.0,  CH3  1.26, s  2, 3, 25 
2  74.9,  C      74.9,  C     
3  59.0,  CH  3.89, dd (4.1, 12.6)  1, 2, 4, 5, 25  59.1,  CH  3.89, dd (3.8, 12.2)  1, 2, 5, 25 
4  28.2,  CH2 
2.13(α), m 
2.26(β), m 
2, 3, 5, 6  28.3,  CH2 
2.10(α), m 
2.24(β), m 
2, 3, 5, 6 
5  37.1,  CH2 
1.52(α), m 
1.80(β), m 
3, 4, 6, 7  37.1,  CH2 
1.53(α), m 
1.80(β), m 
3, 4, 6, 7 
6  74.4,  C      74.3,  C     
7  86.7,  CH  3.08, dd (2.5, 11.0)  6, 8, 9, 11  86.6,  CH  3.08, dd (2.3, 10.8)  6, 8, 9, 11 
8  22.9,  CH2 
1.49(β), m 
1.76(α), m 
7, 10  23.0,  CH2 
1.45(β), m 
1.72(α), m 
7, 10 
9  38.7,  CH2 
1.44(α), m 
1.77(β), m 
7, 10, 11  38.7,  CH2 
1.50(α), m 
1.77(β), m 
7, 10, 11 
10  72.9,  C      72.9,  C     
11  78.9,  CH  3.43, dd (5.7, 11.3)  7, 9, 10, 12, 13  79.1,  CH  3.42, dd (5.7, 11.4)  7, 10, 13 
12  21.8,  CH2 
1.60(β), m 
1.81(α), m 
10, 11, 14  21.8,  CH2 
1.63(β), m 
1.78(α), m 
10, 11, 14 
13  26.6,  CH2 
1.86(β), m 
2.11(α), m 
11, 14  26.3,  CH2 
1.82(β), m 
2.03(α), m 
11, 14 
14  72.5,  CH  4.28, dd (4.0, 8.1)  10, 15, 16, 28  72.4,  CH  4.27, dd (4.8, 7.3)  15, 16, 28 
15  151.3,  C      151.3,  C     
16  29.9,  CH2 
2.12, m 
2.43, m 
14, 15, 28, 18  29.9,  CH2 
2.12, m 
2.46, m 
14, 15, 28 
17  30.3,  CH2 
1.45, m 
1.63, m 
18, 19  28.2,  CH2  1.38  18, 19 
18  76.2,  CH  3.52, dd (1.7, 10.4)  16, 17, 19, 20  77.0,  CH  3.30, dd (1.3, 10.5)  16, 19, 20 
19  86.0,  C      76.1,  C     
20  31.7,  CH2 
1.60, m 
2.12, m 
18, 19, 22  27.9,  CH2 
1.50, m 
1.79, m 
18, 19 
21  26.3,  CH2  1.84, m  19, 22  24.7,  CH2  1.75, m  22 
22  87.6,  CH  3.76, dd (6.0, 9.9)  19, 23, 24, 30  75.2,  CH  3.38, dd (5.1, 10.5)  23, 24, 30 
23  70.5,  C      75.7,  C     
24  24.0,  CH3  1.12, s  22, 23, 30  21.4,  CH3  1.24, s  22, 23, 30 
25  23.6,  CH3  1.39, s  1, 2, 3  23.6,  CH3  1.39, s  1, 2, 3 
26  20.1,  CH3  1.20, s  5, 6, 7  20.0,  CH3  1.20, s  5, 6, 7 
27  19.4,  CH3  1.23, s  9, 10, 11  19.3,  CH3  1.22, s  9, 10, 11 
28  109.8,  CH2 
4.88, bs 
5.05, bs 
14, 15, 16  109.7,  CH2 
4.86, bs 
5.03, bs 
14, 15, 16 
29  23.7,  CH3  1.14, s  18, 19, 20  22.4,  CH3  1.18, s  18, 19, 20 
30  27.7,  CH3  1.21, s  22, 23, 24  30.0,  CH3  1.25, s  22, 23, 24 
a HMBC correlations, optimized for 6 Hz, are from proton(s) stated to the indicated carbon. Mar. Drugs 2011, 9                     
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22-Hydroxy-15(28)-dehydrovenustatriol  (3), was obtained as an amorphous white solid,   
[α]
25
D  +15.2  (c  0.07, CHCl3).  The molecular formula of 3, C30H51O7Br,  deduced by ESI-HRMS  
(m/z 625.2695/627.2723, [M + Na]
+), indicated the presence of an additional oxygen atom with respect 
to dehydrothyrsiferol (1) [7,12]. Comparison of the 
1H and 
13C NMR data of 3 with those reported for 
1 clearly revealed that 3 shares the same carbon skeleton with 1, but contains an additional oxygen 
atom at the C-19→C-24 moiety (Table 2). Thus, a detailed analysis of the 
1H–
1H COSY and HSQC 
spectra confirmed the existence of the same four 
1H–
1H spin systems (Fragments I–IV) observed in the 
C-1→C-18 portion of 1 (Figure 5). However, in contrast with 1, the terminal moiety of the molecule 
contains only a four-proton spin system formed by H2-20 (δH 2.00) and H2-21 (δH 1.80/1.91), missing 
the characteristic H-22 signal.  Finally, we used the HMBC experiment to connect the new  and 
characteristic 
13C signal of C-22 (δC 112.5) with H2-20 (δH 2.00), H3-24 (δH 1.29) and H3-30 (δH 1.31). 
In addition those correlations observed between H3-29 (δH 1.44) and C-18 (δC 84.8), C-19 (δC 86.9) 
and C-20 (δC 29.3) allowed us to build up the structure of the C-18→C-24 portion of 3. 
Figure 4. Biogenetic proposal for the C-16→C-24 moieties of compounds 2 and 3. 
  
Table 2.  NMR  spectroscopic  data (600 MHz, CDCl3, 298 K) for 22-hydroxy-15(28)-
dehydrovenustatriol (3) and 1,2-dehydropseudodehydrothyrsiferol (4). 
  22-Hydroxy-15(28)dehydrovenustatriol (3)  1,2-Dehydropseudodehydrothyrsiferol (4) 
Position  δC, mult.  δH (J in Hz)  HMBC 
a  δC, mult.  δH (J in Hz)  HMBC 
a 
1  31.0,  CH3  1.27, s  2, 3, 25  110.0,  CH2 
4.77, bs 
4.99, bs 
2, 3, 25 
2  74.7,  C      145.3,  C     
3  59.0,  CH  3.89, dd (3.9, 12.5)  1, 2, 5, 25  83.2,  CH  4.36, dd (6.1,8.7)  1, 2, 4, 25 
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Table 2. Cont. 
  22-Hydroxy-15(28)dehydrovenustatriol (3)  1,2-Dehydropseudodehydrothyrsiferol (4) 
Position  δC, mult.  δH (J in Hz)  HMBC 
a  δC, mult.  δH (J in Hz)  HMBC 
a 
4  28.2,  CH2 
2.11(α), m 
2.25(β), m 
2, 3, 5, 6  30.9,  CH2 
1.70, m 
2.04, m 
3, 6 
5  36.9,  CH2 
1.52(α), m 
1.81(β), m 
3, 4, 6, 7, 26  34.2,  CH2 
1.62, m 
2.10, m 
6, 7, 26 
6  74.3,  C      84.1,  C     
7  86.4,  CH  3.08, dd (2.2, 11.2)  6, 9, 11, 26  83.7,  CH  3.37, dd (2.7,11.0)  6, 9, 11, 26 
8  22.7,  CH2 
1.47(β), m 
1.75(α), m 
7, 10  24.6,  CH2 
1.47(β), m 
1.65(α), m 
6, 7, 10 
9  38.5,  CH2 
1.53(α), m 
1.78(β), m 
7, 10, 11  38.4,  CH2 
1.56(β), m 
1.80(α), m 
10, 11 
10  73.0,  C      72.4,  C     
11  78.8,  CH  3.42, dd (5.7, 11.3)  7, 10, 13, 27  78.6,  CH  3.48, dd (5.5,11.6)  9, 10, 13, 27 
12  21.7,  CH2 
1.61(β), m 
1.81(α), m 
10, 11, 14  21.4,  CH2 
1.66(β), m 
1.82(α), m 
10, 11 
13  26.6,  CH2 
1.85(β), m 
2.10(α), m 
11, 14  26.4,  CH2 
1.85(β), m 
2.09(α), m 
11, 14, 15 
14  72.5,  CH  4.26, dd (4.4, 7.4)  15, 16, 28  72.3,  CH  4.28, dd (4.0,7.7)  12, 15, 16, 28 
15  151.0,  C      151.0,  C     
16  29.9,  CH2 
2.12, m 
2.39, m 
14, 15, 28  29.3,  CH2 
2.18, m 
2.46, m 
15, 28 
17  29.5,  CH2 
1.57, m 
1.68, m 
18, 19  29.7,  CH2 
1.48, m 
1.64, m 
15, 18 
18  84.8,  CH  3.55, m  16, 19, 20, 29  76.0,  CH  3.52, d (9.2)  17, 19, 20, 29 
19  86.9,  C      86.1,  C     
20  29.3,  CH2  2.00, m  18, 19  31.3,  CH2 
1.57, m 
2.08, m 
18, 19 
21  32.0,  CH2 
1.80, m 
1.91, m 
19, 22  26.3,  CH2  1.84, m  19, 22 
22  112.5,  C      87.4,  CH  3.76, dd (5.8,10.2)  21, 23, 24, 30 
23  70.4,  C      70.3,  C     
24  25.2,  CH3  1.29, s  22, 23, 24  23.7,  CH3  1.12, s  22, 23, 30 
25  23.3,  CH3  1.40, s  1, 2, 3  17.2,  CH3  1.70, s  1, 2, 3 
26  19.7,  CH3  1.20, s  5, 6, 7  22.7,  CH3  1.17, s  5, 6, 7 
27  19.1,  CH3  1.22, s  9, 10, 11  19.5,  CH3  1.26, s  9, 10, 11 
28  109.4,  CH2 
4.86, bs 
5.05, bs 
14, 15, 16  109.6,  CH2 
4.88, bs 
5.05, bs 
14, 15, 16 
29  17.5,  CH3  1.44, s  18, 19, 20  23.6,  CH3  1.14, s  18, 19, 20 
30  23.6,  CH3  1.31, s  22, 23, 30  27.5,  CH3  1.21, s  22, 23, 24 
a HMBC correlations, optimized for 6 Hz, are from proton(s) stated to the indicated carbon. 
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Figure 5. Selected sections of the COSY and HMBC spectra of compound 3. 
1H–
1H spin 
systems are represented with blue lines and arrows represent significant HMBC correlations.  
 
Comparison of the 
3JH–H coupling constants, 
1H and 
13C chemical shifts together with a detailed 
analysis of the NOESY experiment established the relative configuration of the C-1→C-14 fragment in 
3 as identical to dehydrothyrsiferol (1). However, the absence of NOE correlations between H3-29 with 
H3-24 and H3-30, excluded any definitive conclusion although it clearly suggests a trans configuration 
for this oxolane ring. The relative configuration of this moiety can be proposed making use of a 
biogenetic hypothesis. Thus, the presence of a hemiacetal group at C-22 can be rationalized via an 
intermediate with a carbonyl group at C-22 and by the subsequent cyclization as represented in Figure 4. 
Again, assuming that the biogenesis starts with a common precursor for all the oxaqualenoids isolated 
from Laurencia, the most plausible configuration for the stereogenic centers of this fragment should be 
18R*, 19S* and 22R*. 
Two additional related compounds, 1,2-dehydropseudodehydrothyrsiferol (4) and 
secodehydrothyrsiferol (5) were isolated in this study. Analysis of their ESI-HRMS spectra allowed us 
to establish their molecular formulas as C30H50O6 and C30H50O8 respectively. Comparison of the 
1H 
and 
13C chemical shifts of 1,2-dehydropseudodehydrothyrsiferol (4) with other related compounds 
revealed great similarities with those reported for pseudodehydrothyrsiferol (6) except at the C-1→C-3 
portion of the molecule (Tables 2 and 3). In fact, analysis of the 2D NMR spectra led us to the same 
carbon skeleton. However, the observation of HMBC correlations between the methylene protons H2-1 
(δH  4.77/4.99)  with  C-2 (δC  145.3), C-3 (δC  83.2) and C-25 (δC  17.2)  clearly indicated that the Mar. Drugs 2011, 9                     
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differences between 4 and 6 were due to the dehydration of the hydroxyl group attached to C-2 in 6, 
that yielded  an exocyclic double bond at C-1→C-2 in 4  (Figure 6).  With regard to 
secodehydrothyrsiferol (5), the NMR data showed changes with respect to 6 around the C-1→C-6 
fragment. The 
1H NMR spectrum revealed the existence of two new methyl groups as well as one 
methylene located at α-carbonyl positions. In addition, two new carbonyl groups (one ketone and one 
ester) were easily detected from the 
13C NMR spectrum. Therefore, the structure of 5 was determined 
on the basis of the connectivity observed between H2-4 (δH 2.50) and H2-5 (δH 2.16/2.26) in the COSY 
experiment together with the HMBC correlations of H3-25 (δH 2.15) and H2-4 with C-3 (δC 208.5), 
those of H3-1 (δH 1.98) with C-2 (δC 170.1) and C-6 (δC 84.1) as well as those of H3-26 (δH 1.39) with 
C-5 (δC 29.3), C-6 (δC 84.1) and C-7 (δC 80.0). Comparison of the 
1H and 
13C chemical shifts, 
3JH–H 
coupling constants, together with an analysis of the ROESY experiments of 4 and 5 showed very 
similar results compared to those of compound 6, and therefore the same relative configuration is 
proposed for the new compounds. An important feature in 4 and 5 is the absence of the bromine atom 
in ring A as it is common in the thyrsiferol or venustatriol series. Thus, the biogenetic origin of both 
compounds  could be rationalized by attack of the oxane  oxygen  to the  C-3  position  that bears a 
bromine atom via a 5-exo process, giving an oxonium ion intermediate that would evolve as shown in 
Figure 7 to  yield  both  metabolites  [5]. The biogenetic origin of  5  could  be  rationalized  by a  
Wagner-Meerwein rearrangement. These rearrangements have been confirmed experimentally in many 
cases and are almost always consistent with the participation of an oxonium ion intermediate [13,14]. 
In order to confirm the previous proposal, we induced this rearrangement in dehydrothyrsiferol (1). 
Therefore, 1 was treated with AgNO3 using either methanol:water (1:1) or anhydrous acetonitrile as 
solvents. In the first case, using a methanol:water (1:1) mixture,  the reaction yielded 
pseudodehydrothyrsiferol (6) as well as the methoxy derivatives at C-2 and C-3 positions. The relative 
yields of this reaction could be modulated changing the methanol:water ratio. On the other hand, when 
an aprotic solvent was used, three compounds showing m/z of 506 were identified by LC-MS although 
the main product was 1,2-dehydropseudodehydrothyrsiferol (4) [15,16]. 
Table 3. NMR spectroscopic data (600 MHz, CDCl3, 298 K) for secodehydrothyrsiferol (5) 
and 1,2-pseudodehydrothyrsiferol (6). 
  Secodehydrothyrsiferol (5)  Pseudodehydrothyrsiferol (6) 
Position  δC, mult.  δH (J in Hz)  HMBC 
a  δC, mult.  δH (J in Hz)  HMBC 
a 
1  22.2,  CH3  1.98, s  6, 25  24.0,  CH3  1.11, s  2, 3, 25 
2  170.1,  C      70.6,  C     
3  208.5,  C      86.7,  CH  3.76, dd (5.8, 9.1)  1, 2, 4, 5, 25 
4  38.1,  CH2  2.50, m  3, 5, 6  26.3,  CH2  1.84, m  3, 6 
5  29.3,  CH2 
2.16, m 
2.26, m 
3, 4, 6, 7, 26  35.2,  CH2 
1.66, m 
2.04, m 
6, 7, 26 
6  84.1,  C      84.0,  C     
7  80.0,  CH  3.93, dd (3.9, 9.9)  5, 6, 9, 11, 26  84.0,  CH  3.32, dd (2.6, 11.4)  6, 9, 11, 26 Mar. Drugs 2011, 9                     
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Table 3. Cont. 
  Secodehydrothyrsiferol (5)  Pseudodehydrothyrsiferol (6) 
Position  δC, mult.  δH (J in Hz)  HMBC 
a  δC, mult.  δH (J in Hz)  HMBC 
a 
8  23.6,  CH2  1.56, m  7, 10  24.5,  CH2 
1.51(β), m 
1.66(α), m 
7, 10 
9  38.6,  CH2 
1.57(β), m 
1.81(α), m 
10, 11, 27  38.7,  CH2 
1.57(β), m 
1.81(α), m 
10, 11, 27 
10  72.5,  C      72.8,  C     
11  79.0,  CH  3.46, dd (5.6, 11.4)  9, 10, 13, 27  78.9,  CH  3.46, dd (5.6, 11.7)  9, 10, 13, 27 
12  21.7,  CH2 
1.63(β), m 
1.83(α), m 
10, 11  21.8,  CH2 
1.65(β), m 
1.84(α), m 
10, 11 
13  26.2,  CH2 
1.84(β), m 
2.05(α), m 
11, 14, 15  26.4,  CH2 
1.85(β), m 
2.08(α), m 
11, 14, 15 
14  72.5,  CH  4.28, dd (3.8, 7.5)  13, 15, 16, 28  72.5,  CH  4.29, dd (4.2, 7.1) 
13, 15, 16, 
28 
15  151.1,  C      151.3,  C     
16  29.5,  CH2 
2.16, m 
2.45, m 
15, 28  29.7,  CH2 
2.20, m 
2.46, m 
15, 28 
17  29.9,  CH2 
1.46, m 
1.64, m 
15, 18  29.9,  CH2 
1.48, m 
1.64, m 
15, 18 
18  76.2,  CH  3.52, dd (1.4, 10.4)  19, 20, 29  76.2,  CH  3.53, dd (1.5, 10.8) 
17, 19, 20, 
29 
19  86.1,  C      86.1,  C     
20  31.5,  CH2 
1.57, m 
2.10, m 
18, 19  31.6,  CH2 
1.58, m 
2.10, m 
18, 19 
21  26.6,  CH2  1.84, m  19, 22  26.5,  CH2  1.83, m  19, 22 
22  87.6,  CH  3.76, dd (5.8, 10.1)  23, 24, 30  87.6,  CH  3.76, dd (6.5, 9.8) 
21, 23, 24, 
30 
23  70.4,  C      70.4,  C     
24  23.9,  CH3  1.13, s  22, 23, 30  23.9,  CH3  1.13, s  22, 23, 30 
25  29.9,  CH3  2.15, s  3  27.5,  CH3  1.19, s  1, 2, 3 
26  20.0,  CH3  1.39, s  5, 6, 7  22.7,  CH3  1.14, s  5, 6, 7 
27  19.5,  CH3  1.25, s  9, 10, 11  19.4,  CH3  1.25, s  9, 10, 11 
28  110.0,  CH2 
4.89, bs 
5.05, bs 
14, 15, 16  109.9,  CH2 
4.89, bs 
5.05, bs 
14, 15, 16 
29  23.8,  CH3  1.15, s  18, 19, 20  23.7,  CH3  1.14, s  18, 19, 20 
30  27.7,  CH3  1.22, s  22, 23, 24  27.7,  CH3  1.21, s  22, 23, 24 
a HMBC correlations, optimized for 6 Hz, are from proton(s) stated to the indicated carbon. 
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Figure 6. Selected sections of the COSY and HMBC spectra of compounds 4 and 5. Blue 
lines represent 
1H–
1H spin systems while arrows indicate relevant HMBC correlations.  
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Figure 7. Plausible biogenesis pathway for metabolites showing rings A modifications. 
 
This class of polyether squalene natural products shows a variety of biological properties where its 
cytotoxicity against breast cancer cells is highly significant [5,9,17]. Therefore, the in vitro cytostatic 
activity of 1–5 was assessed by XTT assays [18], using several human cancer cell lines, including 
Jurkat (human T-cell acute leukemia), MM144 (human multiple myeloma), HeLa (human cervical 
carcinoma), and CADO-ES1 (human Ewing’s sarcoma). As  shown in Table 4, Jurkat leukemic  
cells were the most sensitive cells to the tested  polyether compounds. In particular,  iubol  (2),  
22-hydroxy-15(28)-dehydrovenustatriol  (3), and secodehydrothyrsiferol (5) showed the highest 
effectiveness against this cell line (IC50, 2.0–3.5 μM). The capacity of the above compounds to inhibit 
cell proliferation was likely due to their ability to induce apoptosis, as assessed by the appearance of a 
sub-G1/G0  subpopulation in cell cycle analysis,  indicative of DNA breakdown [19], following 
incubation of Jurkat cells with 5 (Figure 8).  
Figure 8. Induction of apoptosis by secodehydrothyrsiferol (5) in T-cell leukemia cells. 
Jurkat cells were treated with 20 µM of 5 for 48 h. Afterwards apoptosis was quantitated as 
the percentage of cells in the sub-G1/G0 region (arrows) in cell cycle analysis by flow 
cytometry. Untreated control cells were run in parallel. The percentage of apoptotic cells is 
indicated in each histogram.  
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Table 4. In vitro growth inhibitory activity of polyether compounds 1–5 on tumor cells. 
Compound 
IC50 (μM) 
Jurkat  MM144  HeLa  CADO-ES1 
1  13.5 ± 1.8  21.5 ± 2.1  34.5 ± 3.2  12.0 ± 1.4 
2  3.5 ± 0.4  13.0 ± 1.9  27.0 ± 2.6  11.0 ± 1.5 
3  2.0 ± 0.2  ND  2.9 ± 0.5  ND 
4  15.5 ± 2.8  16.5 ± 2.5  24.0 ± 3.5  10.6 ± 1.5 
5  2.5 ± 0.3  12.0 ± 1.7  30.0 ± 3.5  12.2 ± 1.6 
Data are shown as mean values ± SD of three independent determinations performed in triplicate. 
ND, not determined. 
Interestingly, the substitution of an H atom in 1 by a hydroxyl group in 3 at C-22 highly potentiated 
the cytostatic activity (Table 4). It is also noteworthy that all the above compounds were active against 
the CADO-ES1 human Ewing’s sarcoma cell line (Table 4) in the range of 10–12 µM, suggesting that 
this type of compound could be suitable in the search for therapeutic lead compounds against both 
sarcoma and T-cell leukemia malignancies.  Doxorubicin, used as a positive control rendered IC50 
values in the order of 10
−7–10
−8 M (data not shown). 
3. Experimental Section 
3.1. General Experimental Procedures 
Optical rotation was determined on a Perkin-Elmer 241 polarimeter. IR spectra were measured on a 
Bruker IFS55 spectrometer. The NMR spectra were obtained with a Bruker 600 Advance instruments. 
Chemical shifts (δ) are reported in ppm and referenced to the residual peak of CHCl3 at 7.26 ppm and 
77.0 ppm for 
1H and 
13C, respectively. The couplings constants are given in Hz. ESI-HRMS was 
performed on a VG AutoSpec FISON spectrometer. HPLC was carried out with a LKB 2248 system 
equipped with a differential diffractometer detector. Silica gel CC and TLC were performed on Silica 
gel Merck 60 G. TLC plates were visualized by spraying with H2SO4/H2O/AcOH (1:4:20) and heating. 
3.2. Plant Material 
The specimens of Laurencia viridis were collected in March 2008 in Callao Salvaje, Paraiso Floral, 
Adeje (Tenerife, Canary Island). A voucher specimen was deposited at the herbarium of the La Laguna 
University, Department of Vegetal Biology, Botany, Tenerife. 
3.3. Extraction and Chromatographic Separation 
The fresh alga was extracted with a 1:1 mixture of CHCl3:MeOH at room temperature. The extract 
was evaporated in vacuo to leave dark-green viscous oil (83.0 g, 1.5% dry weight). The crude extract 
was chromatographed on a Sephadex LH-20 column using CHCl3:MeOH (1:1). Fractions that were 
similar in composition as shown by TLC were combined to give four fractions. The second fraction 
(53.4 g) was further separated by silica gel column eluted with increasing concentrations of EtOAc in 
n-hexane.  The third fraction (4.43 g) was  chromatographed by a medium pressure silica gel 
chromatography Lobar LiChroprep-Si60with CH2Cl2:acetone (8:2) as eluent. Final purification was Mar. Drugs 2011, 9                     
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carried out by HPLC employing µ-Porasil column and using n-Hex:EtOAc,  n-Hex:acetone and 
CH2Cl2:acetone in different proportions affording the pure new compounds,  iubol  (2) (2.70 mg),   
22-hydroxy-15(28)-dehydrovenustatriol  (3) (0.60 mg), 1,2-dehydropseudodehydrothyrsiferol (4)  
(5.13 mg) and secodehydrothyrsiferol (5) (0.80 mg). 
Iubol (2): Amorphous white solid; [α]
25
D +14.8 (c 0.27, CHCl3); IRνmax (CHCl3) 3422, 2950, 2868, 
1649, 1457, 1377 and 1098 cm
−1; ESI-MS m/z 611, 609, 507, 506, 445, 443, 207 and 205; ESI-HRMS 
m/z 611.3607 (Calcd. for C30H51O6
81BrNa, 611.3610, [M + Na]
+); 
1H and 
13C data NMR see Table 1. 
22-Hydroxy-15(28)-dehydrovenustatriol (3): Amorphous white solid; [α]
25
D +15.2 (c 0.07, CHCl3); 
IRνmax(CHCl3) 3494, 2956, 2872, 1465, 1381 and 1102 cm
−1; ESI-MS m/z 627, 625, 609, 607, 413, 
301 and 277; ESI-HRMS m/z 627.2723 (Calcd. for C30H51O7
81BrNa, 627.2695, [M + Na]
 +); 
1H and 
13C data NMR see Table 2. 
1,2-Dehydropseudodehydrothyrsiferol (4): Amorphous white solid; [α]
25
D −4.9 (c 0.51, CHCl3); 
IRνmax (CHCl3) 3396, 2971, 2870, 1453, 1375 and 1093 cm
−1; ESI-MS m/z 506, 488, 380, 363, 209, 
143 and 125; ESI-HRMS m/z 506.3627 (Calcd. for C30H50O6, 506.3607, [M]
+); 
1H and 
13C data NMR 
see Table 2. 
Secodehydrothyrsiferol (5): Amorphous white solid; [α]
25
D +2.5 (c 0.08, CHCl3); IRνmax (CHCl3) 
2967, 2869, 1724, 1375 and 1096 cm
−1; ESI-MS m/z 562, 561, 547, 413, 301 and 236; ESI-HRMS  
m/z 561.3407 (Calcd. for C30H50O8Na, 561.3403, [M + Na]
+); 
1H and 
13C data NMR see Table 3. 
3.4. Chemical Correlations 
To a solution of dehydrothyrsiferol (1) (5.0 mg, 8.5 μmol) in anhydrous acetonitrile (1 mL) was 
added AgNO3 (2.2 mg, 12.7 μmol). The solution was stirred for one hour at 40 °C and the resulting 
material was filtered off and concentrated under reduced pressure. The crude material was 
chromatographed in HPLC (µ-Porasil column, n-Hex/AcOEt/MeOH14:5:1, flow rate 1 mL/min) to 
afford the 1,2-dehydropseudodehydrothyrsiferol 1.0 mg, (2.0 μmol) [14]. On other hand, To a mixture 
of dehydrothyrsiferol (1) (10 mg, 17 μmol) in 1 mL MeOH:H2O (1:1) was added AgNO3 (4.4 mg,  
25.4 μmol) and the reaction solution was stirred for 30 min a room temperature. The resulting solution 
was filtered off and the 2 mL of MeOH:H2O was removed in vacuo. The crude oil was purified in 
HPLC (µ-Porasil column, CH2Cl2/MeOH 19:1, flow rate 0.5 mL/min) afforded 4.8 mg (9.1 μmol) of 
pseudodehydrothyrsiferol (6) 3.5 mg (6.5 μmol) of 2-methoxypseudodehydrothyrsiferol and 0.7 mg 
(1.3 μmol) of 2-dehydroxy-3-methoxypseudodehydrothyrsiferol [15]. 
3.5. Cell Culture 
Jurkat (human T-cell acute leukaemia), MM144 (human multiple myeloma), HeLa (human cervical 
carcinoma), and CADO-ES1 (human Ewing’s sarcoma) cells were cultured in RPMI-1640 (Jurkat, 
MM144, CADO-ES1) or DMEM (HeLa) culture medium containing 10% (v/v) heat-inactivated fetal 
bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C 
in air containing 95% humidity and 5% CO2. Cells were periodically tested for Mycoplasma infection 
using the MycoAlert
© Mycoplasma detection kit (Lonza, Basel, Switzerland) as well as the Venor
©GeM 
Advance Mycoplasma PCR detection Kit (Minerva Biolabs, Berlin, Germany), and found to be negative. Mar. Drugs 2011, 9                     
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3.6. Cell Growth Inhibition Assay 
The effect of compounds 1–5 in the proliferation of human tumor cell lines (cytostatic activity) was 
determined as previously described by using the XTT (sodium 3'-[1-(phenylaminocarbonyl)-3,4-
tetrazolium]-bis(4-methoxy-6-nitro)benzenesulfonic acid hydrate)  cell proliferation kit (Roche 
Molecular Biochemicals, Mannheim, Germany) as previously described [18]. Cells (1.5–5.0 × 10
3 in 
100 μL) were incubated in RPMI-1640 (Jurkat, MM144, CADO-ES-1) or DMEM (HeLa) culture 
medium containing 10% heat-inactivated FBS, in the absence and in the presence of the indicated 
compounds at a concentration range of 10
−4 to 10
−9 M, in 96-well flat-bottomed microtiter plates, and 
following 72 h of incubation at 37 °C in a humidified atmosphere of air/CO2 (19/1) the XTT assay was 
performed. Measurements were done in triplicate, and each experiment was repeated three times. The 
IC50 (50% inhibitory concentration) value, defined as the drug concentration required to cause 50% 
inhibition in the cellular proliferation with respect to the untreated controls, was determined for each 
compound. Data are shown as means ± standard deviation (SD) of three independent experiments, 
each performed in triplicate. 
3.7. Apoptosis Assay 
Quantitation of apoptotic cells was calculated by fluorescence flow cytometry as the percentage of 
cells in the sub-G1/G0 region (hypodiploidy) in cell cycle analysis as previously described [19], by 
using a Becton Dickinson FACSCalibur flow cytometer (San Jose, CA, USA). 
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